Drug intelligence / Profile preview

Iminodyn-17

Development stage: Unknown
Lead developer: Children's Medical Research Institute
Modality: Small Molecules
Administration: Incubation (cell-based Assays), Intramuscular

Overview

Iminodyn-17 is a small molecule belonging to the iminochromene ("iminodyn") chemical series, developed as a dynamin inhibitor. It demonstrates inhibition of dynamin I and II in enzymatic assays. However, it is notable for its lack of effect on dynamin-mediated endocytosis in cells, which makes it a valuable negative control for cell-based assays. Dynamin is a large GTPase enzyme critical for various forms of endocytosis and plays a role in cellular processes such as vesicle trafficking, Golgi function, organelle division, and cell migration.

Brand names: Iminodyn-17™
Other names: N,N-(ethane-1,2-diyl)bis(7,8-dihydroxy-2-iminochromene-3-carboxamide) (17)

Targets

DNM2 (Dynamin 2)DNM1 (Dynamin 1)

Beyond the preview

Go deeper on Iminodyn-17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iminodyn-17.

Explore the full profile